| OCR Text |
Show REFERENCES Alber OS, Sonsalla PK (1995) Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents. J Pharmacol Exp Ther275: 1104-1114. Angulo JA, Angulo N, Yu J (2004) Antagonists of the neurokinin-1 or dopamine 01 receptors confer protection from methamphetamine on dopamine terminals of the mouse striatum. Ann N Y Acad Sci 1025:171-180. Asanuma M, Miyazaki I, Ogawa N (2003) Oopamine- or I-dopa-induced the role of dopamine quinine formation and tyrosinase in a model neurotoxicity: of Parkinson's disease. Neurotox Res 5: 165-176. Barr AM, Panenka WJ, MacEwan GW, Thornton AE, Lang OJ, Honer WG, Lecomte T (2006) The need for speed: an addiction. J Psychiatry Neurosci 31: 301-313. Baucum update on methamphetamine II AJ, Rau KS, Riddle EL, Hanson GR, Fleckenstein AE (2004) Methamphetamine increases dopamine transporter higher molecular weight complex formation via a dopamine- and hyperthermia-associated mechanism. J Neurosci 24:3436-3443. Bauman AL, Apparsundaram S, Ramamoorthy S, Wadzinski BE, Vaughan RA, Blakely RO (2000) Cocaine antidepressant-sensitive biogenic amine transporters exist in regulated complexes with protein phosphatase 2A. J Neurosci 20: 75717578. Berman SB, Zigmond MJ, transporter function: Hastings TG (1996) Modification of dopamine J oxygen species and dopamine. effect of reactive Neurochem 67: 593-600. Bell SB (1973) The experimental reproduction of amphetamine psychosis. Arch Gen Psychiatry 29: 35-40. Block ML, Hong J-S (2007) Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochem Soc Trans 35: 1127-1132. |
